Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Pathophysiology of cutaneous T-cell lymphomas: Perspective from A French Referral Centre.

Masson A, Lazaridou I, Moins-Teisserenc H, Ram-Wolff C, Giustiniani J, Bagot M, Battistella M, Bensussan A

Immunol Lett. 2024 05 25;:106871

In vitro effects of wound-dressings on key wound healing properties of dermal fibroblasts.

Peltier S, Adib Y, Nicosia L, Ly Ka So S, Da Silva C, Serror K, Duciel L, Proust R, Mimoun M, Bagot M, Bensussan A, des Courtils C, Michel L

Exp Dermatol. 2024 05;33(5):e15098

CD39 is expressed by a wide range of cutaneous T-cell lymphomas.

Battesti G, Thonnart N, Bozonnat A, Ram-Wolff C, de Masson A, Bensussan A, Bagot M, Marie-Cardine A, Battistella M

Skin Health Dis. 2024 04;4(2):e334

Targeting TGF-beta activation in cutaneous T-cell lymphomas.

Giustiniani J, Anh Ta V, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, Masson A

J Invest Dermatol. 2024 03 28;:

Early elevated IFNα is a key mediator of HIV pathogenesis.

Buanec HL, Schiavon V, Merandet M, How-Kit A, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Song H, Sajadi MM, Kottilil S, Gallo RC, Zagury D

Commun Med (Lond). 2024 03 19;4(1):53

IFNα induces CCR5 in CD4 T cells of HIV patients causing pathogenic elevation.

Le Buanec H, Schiavon V, Merandet M, How-Kit A, Song H, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Sajadi MM, Kottilil S, Zagury D, Gallo RC

Commun Med (Lond). 2024 03 19;4(1):52

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.

Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y, Foussat A, Potteaux S, Bensussan A, Marie-Cardine A

Breast Cancer Res. 2024 02 15;26(1):28

The allele corresponds to a very large haploblock likely explaining its massive effect for HIV-1 elite control.

Rahmouni M, De Marco L, Spadoni JL, Tison M, Medina-Santos R, Labib T, Noirel J, Tamouza R, Limou S, Delaneau O, Fellay J, Bensussan A, Le Clerc S, McLaren PJ, Zagury JF

Front Immunol. 2023 12 11;14:1305856

Fc receptors act as innate immune receptors during infection?

Laassili C, Ben El Hend F, Benzidane R, Oumeslakht L, Aziz AI, El Fatimy R, Bensussan A, Ben Mkaddem S

Front Immunol. 2023 07 26;14:1188497

Exploring the non-lymphocytic cutaneous microenvironment in advanced cutaneous T-cell lymphomas using single-cell RNA-sequencing.

Calugareanu A, de Masson A, Battistella M, Michel L, Ram-Wolff C, Bouaziz JD, Peltier S, Bensussan A, Bagot M, Dobos G

J Invest Dermatol. 2023 04 24;:

Modulation of NK cell activation by exogenous calcium from alginate dressings .

Adib Y, Boy M, Serror K, Dulphy N, des Courtils C, Duciel L, Boccara D, Mimoun M, Samardzic M, Bagot M, Bensussan A, Michel L

Front Immunol. 2023 04 6;14:1141047

Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3.

Arulanandam A, Lin L, Chang HM, Cerutti M, Choblet S, Gao P, Rath A, Bensussan A, Kadouche J, Teper D, Mandelboim O, Li W

Cells. 2023 03 24;12(7):

CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas.

Van Anh TA, Battistella M, Zhao LP, Dobos G, Ram-Wolff C, Madelaine I, Bories JC, Tournilhac O, Rouanet J, Veyrat-Masson R, Bouaziz JD, Marie-Cardine A, Bagot M, Bensussan A, Moins-Teisserenc H, De Masson A

J Invest Dermatol. 2023 01 27;:

Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.

Aziz AI, Nguyen LC, Oumeslakht L, Bensussan A, Ben Mkaddem S

Cannabis Cannabinoid Res. 2022 11 22;:

CD160 receptor in CLL: Current state and future avenues.

Oumeslakht L, Aziz AI, Bensussan A, Ben Mkaddem S

Front Immunol. 2022 11 7;13:1028013

Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Sézary Patient-Derived Xenograft Mouse Model.

Habault J, Thonnart N, Ram-Wolff C, Bagot M, Bensussan A, Poyet JL, Marie-Cardine A

Cells. 2022 09 20;11(19):

Cytotoxic activity of peripheral blood mononuclear cells in patients with endometriosis: A cross-sectional study.

Muharam R, Bustami A, Gusti Mansur I, Zulkifli Jacoeb T, Giustiniani J, Schiavon V, Bensussan A

Int J Reprod Biomed. 2022 08;20(8):691-700

The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.

Coillard L, Guaddachi F, Ralu M, Brabencova E, Garbar C, Bensussan A, Le Bras M, Lehmann-Che J, Jauliac S

Front Oncol. 2022 06 30;12:804868

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.

Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A

Blood Adv. 2022 06 14;6(11):3507-3512

Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome.

Sonigo G, Bozonnat A, Dumont M, Thonnart N, Ram-Wolff C, de Masson A, Bagot M, Bensussan A, Marie-Cardine A

Blood. 2022 04 28;139(17):2712-2716

Cutaneous Wound Healing: A Review about Innate Immune Response and Current Therapeutic Applications.

Adib Y, Bensussan A, Michel L

Mediators Inflamm. 2022 04 25;2022:5344085

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.

Gauci ML, Giustiniani J, Lepelletier C, Garbar C, Thonnart N, Dumaz N, Foussat A, Lebbé C, Bensussan A, Marie-Cardine A

Cancer Immunol Immunother. 2022 Apr 15;:

Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing.

Dobos G, Calugareanu A, Michel L, Battistella M, Ram-Wolff C, Bouaziz JD, Bensussan A, de Masson A, Bagot M

Eur J Cancer. 2021 10;156 Suppl 1:S3-S4

ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells.

Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, De Croos A, Gorvel L, Goubard A, Bouabdallah R, Schiano JM, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Delaporte E, Olive D

Eur J Cancer. 2021 10;156 Suppl 1:S23-S24

Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.

Dobos G, Miladi M, Roelens M, Ram-Wolff C, de Masson A, Michel L, Battistella M, Mourah S, Bensussan A, Moins-Teisserenc H, Bagot M

Eur J Cancer. 2021 10;156 Suppl 1:S6-S7

Increased CD8CD28 circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis.

Cassius C, Branchtein M, Battistella M, Amode R, Lepelletier C, Jachiet M, de Masson A, Frumholtz L, Chasset F, Monfort JB, Bachmeyer C, Bengoufa D, Cordoliani F, Bagot M, Bensussan A, Le Buanec H, Bouaziz JD

J Am Acad Dermatol. 2021 09;85(3):755-758

PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4 T Lymphocytes.

Habault J, Thonnart N, Pasquereau-Kotula E, Bagot M, Bensussan A, Villoutreix BO, Marie-Cardine A, Poyet JL

J Invest Dermatol. 2021 09;141(9):2261-2271.e5

The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort.

Dobos G, De Cevins C, Ly Ka So S, Jean-Louis F, Mathieu S, Ram-Wolff C, Resche-Rigon M, Bensussan A, Bagot M, Michel L

Br J Dermatol. 2021 08;185(2):405-411

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.

Fayon M, Martinez-Cingolani C, Abecassis A, Roders N, Nelson E, Choisy C, Talbot A, Bensussan A, Fermand JP, Arnulf B, Bories JC

Haematologica. 2021 04 1;106(4):1193-1197

Expansion of Circulating CD49bLAG3 Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease.

Talvard-Balland N, Sutra Del Galy A, Michonneau D, Le Buanec H, Chasset F, Robin M, Peffault de Latour R, Xhaard A, Sicre de Fontbrune F, Parquet N, Duchez S, Schiavon V, Rybojad M, Bergeron-Lafaurie A, Bagot M, Bensussan A, Caillat-Zucman S, Socié G, Bouaziz JD, de Masson A

J Invest Dermatol. 2021 01;141(1):193-197.e2

[Skin aging: Pathophysiology and innovative therapies].

Boismal F, Serror K, Dobos G, Zuelgaray E, Bensussan A, Michel L

Med Sci (Paris). 2020 12;36(12):1163-1172

ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, De Croos A, Salvado C, Gorvel L, Goubard A, Collette Y, Bouabdallah R, Schiano JM, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Berbis P, Olive D

Blood Adv. 2020 10 27;4(20):5203-5214

Persistent deficiency of mucosal-associated invariant T cells during dermatomyositis.

Cassius C, Branchtein M, Battistella M, Amode R, Lepelletier C, Jachiet M, de Masson A, Frumholtz L, Chasset F, Amoura Z, Mathian A, Samri A, Monfort JB, Bachmeyer C, Bengoufa D, Cordoliani F, Bagot M, Bensussan A, Bouaziz JD, Le Buanec H

Rheumatology (Oxford). 2020 09 1;59(9):2282-2286

MDA5 Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-κ Transcript.

Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A, Lepelletier C, Jachiet M, de Masson A, Frumholtz L, Cordoliani F, Boccara D, Lehmann-Che J, Wong J, Dubanchet S, Alberdi AJ, Merandet M, Bagot M, Bensussan A, Bouaziz JD, Le Buanec H

J Invest Dermatol. 2020 06;140(6):1276-1279.e7

Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.

Roelens M, de Masson A, Ram-Wolff C, Maki G, Cayuela JM, Marie-Cardine A, Bensussan A, Toubert A, Bagot M, Moins-Teisserenc H

Br J Dermatol. 2020 06;182(6):1415-1422

In vivo anti-MUC1 tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies.

Pichinuk E, Chalik M, Benhar I, Ginat-Koton R, Ziv R, Smorodinsky NI, Haran G, Garbar C, Bensussan A, Meeker A, Guillaume T, Rubinstein DB, Wreschner DH

Cancer Immunol. Immunother.. 2020 Mar 26;:

[A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].

Gros L, Paturel C, Perrot I, Bensussan A, Eliaou JF, Bastid J, Bonnefoy N

Med Sci (Paris). 2020 02;36(2):112-115

Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.

Hocine HR, Brunel S, Chen Q, Giustiniani J, San Roman MJ, Ferrat YJ, Palacios I, de la Rosa O, Lombardo E, Bensussan A, Charron D, Jabrane-Ferrat N, Al-Daccak R

Stem Cells Transl Med. 2019 09;8(9):911-924

Atypical and Mutations in Mucosal Melanoma.

Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C

Cancers (Basel). 2019 08 8;11(8):

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA, Kim YH

Lancet Oncol. 2019 08;20(8):1160-1170

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N

Cell Rep. 2019 05 21;27(8):2411-2425.e9

Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes.

Meng Q, Zaidi AK, Sedy J, Bensussan A, Popkin DL

J Immunol. 2019 04 1;202(7):2057-2068

Microenvironment tailors nTreg structure and function.

Schiavon V, Duchez S, Branchtein M, How-Kit A, Cassius C, Daunay A, Shen Y, Dubanchet S, Colisson R, Vanneaux V, Pruvost A, Roucairol C, Setterblad N, Bouaziz JD, Boissier MC, Semerano L, Graux C, Bensussan A, Burny A, Gallo R, Zagury D, Le Buanec H

Proc Natl Acad Sci U S A. 2019 03 26;116(13):6298-6307

Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients.

Bensussan A, Janela B, Thonnart N, Bagot M, Musette P, Ginhoux F, Marie-Cardine A

J Invest Dermatol. 2019 03;139(3):725-728

Increased expression of PD1 and CD39 on CD3 CD4 skin T cells in the elderly.

Zuelgaray E, Boccara D, Ly Ka So S, Boismal F, Mimoun M, Bagot M, Bensussan A, Bouaziz JD, Michel L

Exp Dermatol. 2019 01;28(1):80-82

The Interleukin-17 Family of Cytokines in Breast Cancer.

Fabre JAS, Giustinniani J, Garbar C, Merrouche Y, Antonicelli F, Bensussan A

Int J Mol Sci. 2018 Dec 4;19(12):

Cytokine levels in persistent skin lesions of adult-onset Still disease.

Zuelgaray E, Battistella M, Vignon-Pennamen MD, Ly Ka So S, Rybojad M, Petit A, Cordoliani F, Boccara D, Mimoun M, Lipsker D, Chasset F, Bensussan A, Bagot M, Bouaziz JD, Michel L,

J. Am. Acad. Dermatol.. 2018 Sep 20;:

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M

Br J Dermatol. 2018 07;179(1):197-199

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P

Invest Ophthalmol Vis Sci. 2018 06 1;59(7):2687-2698

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.

Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C

Invest. Ophthalmol. Vis. Sci.. 2018 Jun 1;59(7):2679-2686

Impact of prednisone in patients with repeated embryo implantation failures: Beneficial or deleterious?

Lédée N, Prat-Ellenberg L, Petitbarat M, Chevrier L, Simon C, Irani EE, Vitoux D, Bensussan A, Chaouat G

J Reprod Immunol. 2018 06;127:11-15

Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.

Benfodda M, Gazal S, Descamps V, Basset-Seguin N, Deschamps L, Thomas L, Lebbe C, Saiag P, Zanetti R, Sacchetto L, Chiorino G, Scatolini M, Grandchamp B, Bensussan A, Soufir N

Genes Chromosomes Cancer. 2018 06;57(6):294-303

Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016.

Hurabielle C, Battistella M, Ram-Wolff C, Fite C, Meignin V, Rivet J, Vignon-Pennamen MD, de Risi-Pugliese T, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Bagot M

Ann Dermatol Venereol. 2018 04 14;145(6-7):405-412

Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape.

Garbar C, Mascaux C, Merrouche Y, Bensussan A

Cancer Manag Res. 2018 ;10:1051-1059

KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.

Battistella M, Leboeuf C, Ram-Wolff C, Hurabielle C, Bonnafous C, Sicard H, Bensussan A, Bagot M, Janin A

Blood. 2017 12 28;130(26):2900-2902

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N

Oncotarget. 2017 12 26;8(69):113360-113372

Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways.

Michel L, Reygagne P, Benech P, Jean-Louis F, Scalvino S, Ly Ka So S, Hamidou Z, Bianovici S, Pouch J, Ducos B, Bonnet M, Bensussan A, Patatian A, Lati E, Wdzieczak-Bakala J, Choulot JC, Loing E, Hocquaux M

Br J Dermatol. 2017 11;177(5):1322-1336

Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair.

Dam N, Hocine HR, Palacios I, DelaRosa O, Menta R, Charron D, Bensussan A, El Costa H, Jabrane-Ferrat N, Dalemans W, Lombardo E, Al-Daccak R

Front Immunol. 2017 10 26;8:1413

Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity.

Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A, Alberdi A, Maki G, Homyrda L, Bensussan A, Bagot M, Toubert A, Moins-Teisserenc H

Blood. 2017 09 21;130(12):1468-1471

Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.

Schmitt C, Marie-Cardine A, Bensussan A

Front Immunol. 2017 08 30;8:1010

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.

Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A

Sci Rep. 2017 Aug;7(1):7201

Up-and-down immunity of pregnancy in humans.

Le Bouteiller P, Bensussan A

F1000Res. 2017 07 25;6:1216

Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.

Hurabielle C, Thonnart N, Ram-Wolff C, Sicard H, Bensussan A, Bagot M, Marie-Cardine A

Clin Cancer Res. 2017 07 15;23(14):3619-3627

PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.

Delyon J, Servy A, Laugier F, André J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbé C, Dumaz N

Oncogene. 2017 06 8;36(23):3252-3262

Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation.

Lepelletier C, Bengoufa D, Lyes Z, de Masson A, Chasset F, Jachiet M, Michonneau D, Robin M, Peffault de Latour R, Sicre de Fontbrune F, Tandjaoui-Lambiotte Y, Bensussan A, Rybojad M, Tazi A, Bagot M, Socié G, Bergeron A, Bouaziz JD

JAMA Dermatol. 2017 02 1;153(2):184-188

Uterine immune profiling for increasing live birth rate: A one-to-one matched cohort study.

Lédée N, Prat-Ellenberg L, Chevrier L, Balet R, Simon C, Lenoble C, Irani EE, Bouret D, Cassuto G, Vitoux D, Vezmar K, Bensussan A, Chaouat G, Petitbarat M

J Reprod Immunol. 2017 02;119:23-30

Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R

Sci Rep. 2017 01 24;7:41125

Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage.

Brun C, Ly Ka So S, Maginiot F, Bensussan A, Michel L, Larghero J, Wong H, Oddos T, Cras A

Exp Dermatol. 2016 11;25(11):906-909

Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

Laugier F, Delyon J, André J, Bensussan A, Dumaz N

Oncogene. 2016 09 22;35(38):5070-7

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.

Vallarelli AF, Rachakonda PS, André J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N

Oncotarget. 2016 08 16;7(33):53127-53136

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.

Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J

Oncotarget. 2016 Aug;7(33):53350-53361

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L

Br J Dermatol. 2016 08;175(2):325-33

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.

Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R

Int J Mol Sci. 2016 Aug;17(9):

APRIL levels are associated with disease activity in human chronic graft-versus-host disease.

Chasset F, de Masson A, Le Buanec H, Xhaard A, de Fontbrune FS, Robin M, Rybojad M, Parquet N, Brignier AC, Coman T, Bengoufa D, Bergeron A, Peffault de Latour R, Bagot M, Bensussan A, Socié G, Bouaziz JD

Haematologica. 2016 07;101(7):e312-5

Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.

Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, Tosi I, Morris SL, Moriarty B, Booken N, Felcht M, Quaglino P, Ponti R, Barberio E, Ram-Wolff C, Jäntti K, Ranki A, Bernengo MG, Klemke CD, Bensussan A, Michel L, Whittaker S, Bagot M, Tensen CP, Willemze R, Vermeer MH

J Invest Dermatol. 2016 07;136(7):1364-1372

Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes.

De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A

Oncoimmunology. 2016 May;5(5):e1127493

Trem-1 is not crucial in psoriasiform imiquimod-induced skin inflammation in mice.

Joffre J, Hau E, Zeboudj L, Laurans L, Battistella M, Boufenzer A, Masson A, Le Buanec H, Cochaud S, Bagot M, Bensussan A, Gibot S, Bouaziz JD, Ait-Oufella H

Exp Dermatol. 2016 05;25(5):400-2

PARKIN Inactivation Links Parkinson's Disease to Melanoma.

Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N

J Natl Cancer Inst. 2016 03;108(3):

The Uterine Immune Profile May Help Women With Repeated Unexplained Embryo Implantation Failure After In Vitro Fertilization.

Lédée N, Petitbarat M, Chevrier L, Vitoux D, Vezmar K, Rahmati M, Dubanchet S, Gahéry H, Bensussan A, Chaouat G

Am J Reprod Immunol. 2016 03;75(3):388-401

[Immunopathology of psoriasis: from bench to bedside].

de Masson A, Bouaziz JD, Battistella M, Bagot M, Bensussan A

Med Sci (Paris). 2016 03;32(3):253-9

Phenotypic and functional changes in dermal primary fibroblasts isolated from intrinsically aged human skin.

Brun C, Jean-Louis F, Oddos T, Bagot M, Bensussan A, Michel L

Exp Dermatol. 2016 02;25(2):113-9

Evidence of Th1, Th17 and Tc17 cells in psoriasiform chronic graft-versus-host disease.

Chasset F, Le Buanec H, Sicre de Fontbrune F, de Masson A, Rivet J, Bergeron A, Bagot M, Socié G, Bensussan A, Bouaziz JD

Exp Dermatol. 2016 01;25(1):64-5

Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides.

Hurabielle C, Michel L, Ram-Wolff C, Battistella M, Jean-Louis F, Beylot-Barry M, d'Incan M, Bensussan A, Bagot M

J Invest Dermatol. 2016 01;136(1):317-20

MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA.

Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH

PLoS ONE. 2016 ;11(10):e0165031

CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology.

Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin BQ, Malavasi F, Mortari F, Schwartz-Albiez R, Stockinger H, van Zelm MC, Zola H, Clark G

J Immunol. 2015 11 15;195(10):4555-63

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.

Laugier F, Finet-Benyair A, André J, Rachakonda PS, Kumar R, Bensussan A, Dumaz N

Oncotarget. 2015 09 29;6(29):28120-31

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A

Oncoimmunology. 2015 09;4(9):e1022306

Deficient regulatory B cells in human chronic graft-versus-host disease.

de Masson A, Socié G, Bagot M, Bensussan A, Bouaziz JD

Oncoimmunology. 2015 07;4(7):e1016707

Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside.

Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N

J Reprod Immunol. 2015 06;109:1-6

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF

Oncoimmunology. 2015 05;4(5):e1003015

Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.

Ibarrola-Villava M, Kumar R, Nagore E, Benfodda M, Guedj M, Gazal S, Hu HH, Guan J, Rachkonda PS, Descamps V, Basset-Seguin N, Bensussan A, Bagot M, Saiag P, Schadendorf D, Martin-Gonzalez M, Mayor M, Grandchamp B, Ribas G, Soufir N

Int J Cancer. 2015 05 1;136(9):2109-19

Lack of evidence that HACE1 is not a tumor suppressor gene in NKTCL: to the editor-in-chief. Authors' reply.

Schmitt C, Sako N, Bagot M, Bensussan A

Am J Pathol. 2015 04;185(4):1168

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease.

de Masson A, Bouaziz JD, Le Buanec H, Robin M, O'Meara A, Parquet N, Rybojad M, Hau E, Monfort JB, Branchtein M, Michonneau D, Dessirier V, Sicre de Fontbrune F, Bergeron A, Itzykson R, Dhédin N, Bengoufa D, Peffault de Latour R, Xhaard A, Bagot M, Bensussan A, Socié G

Blood. 2015 03 12;125(11):1830-9

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF

Cancer Immunol Res. 2015 03;3(3):254-65

Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

Garbar C, Mascaux C, Giustiniani J, Salesse S, Debelle L, Antonicelli F, Merrouche Y, Bensussan A

Int J Clin Exp Pathol. 2015 May 1;8(5):4344-55. eCollection 2015.

CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.

Moins-Teisserenc H, Daubord M, Clave E, Douay C, Félix J, Marie-Cardine A, Ram-Wolff C, Maki G, Beldjord K, Homyrda L, Michel L, Bensussan A, Toubert A, Bagot M

J Invest Dermatol. 2015 01;135(1):247-257